We are a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Our portfolio of product candidates includes istaroxime, a Phase 2 candidate that inhibits the sodium-potassium ATPase and also activates sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, for acute heart failure and/or associated cardiogenic shock; preclinic…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$40M
▲ +91.2% YoY
Op. Margin
–
ROIC
-380.94%
▼ -64.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$15M
▼ -14.6% YoY
Op. Cash Flow (TTM)
-$15M
▼ -14.6% YoY
Net Debt
$580K
Cash & Equiv.
$204K
3Y CAGR: -54.1%
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with WINT
Windtree Therapeutics (WINT) in three numbers
Questions about Windtree Therapeutics
Is Windtree Therapeutics (WINT) overvalued?
Windtree Therapeutics trades at 0.00 times earnings. Intrinsiqq's fair value calculator has no opening value for WINT, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Windtree Therapeutics a high-quality business?
Windtree Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is revenue growth at -54.1%. The Quality tab shows every check against its target.
Does Windtree Therapeutics (WINT) pay a dividend, and how much?
Yes. Windtree Therapeutics (WINT) pays a dividend: $2.56 per share over the last twelve months, a dividend yield of 3248.41% at the latest close. The Dividends tab has the full payment history and the safety score.
Source: 10-Q filed 14 Nov 2025 (period ending 30 Sept 2025), SEC. Price: last close 3 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in WINT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing WINT
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.